Adaptimmune Q2 Tecelra sales $11.1M (+150% vs Q1); sells assets to US WorldMeds for $55M upfront

Adaptimmune Therapeutics PLC

2025-Q2 EPS reported -$0.05 revenue$20,962,000

Q2 Tecelra revenue $11.1M from 16 patients invoiced, >150% growth over Q1 2025.
Definitive agreement to sell TECELRA, lete-cel, afami-cel, uza-cel to US WorldMeds for $55M upfront plus up to $30M milestones.
Debt facility with Hercules Capital repaid after transaction close on July 31, 2025.
Net loss $30.3M in Q2 2025 vs profit $69.5M in Q2 2024; cash $26.1M as of June 30.
Restructuring to focus on remaining PRAME and CD70 directed T-cell therapy assets.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.